Table 1 Main characteristics of the 14 studies included in the meta-analysis
| Â | Â | Patients (n) | Average age (year) | Treatment design | Â | |||
|---|---|---|---|---|---|---|---|---|
Study | Type | Con (M/F) | Com (M/F) | Con | Com | Con | Com | JADAD score |
Hu 2013 [28] | N | 21/9 | 29/14 | 47.1 | 45.3 | TACE | TACE+ Sorafenib | 4 |
Wu 2010 [29] | N | 21/4 | 20/5 | – | – | TACE | TACE+ Sorafenib | 6 |
Jiang 2010 [15] | R | 23/7 | 24/6 | 58.0 | 56.0 | TACE | TACE+ Sorafenib | 4 |
Chen 2012 [30] | R | 17/11 | 20/8 | – | – | TACE | TACE+ Sorafenib | 5 |
Wei 2009 [31] | N | 22/8 | 24/6 | – | – | TACE | TACE+ Sorafenib | 5 |
Wei 2012 [16] | N | 42/2 | 42/2 | 53.0 | 53.0 | TACE | TACE+ Sorafenib | 5 |
Yu 2011 [32] | R | 20/5 | 21/4 | 45.3 | 45.3 | TACE | TACE+ Sorafenib | 5 |
Yang 2013 [33] | R | – | – | – | – | TACE | TACE+ Sorafenib | 5 |
Ye 2013 [17] | N | 30/5 | 32/3 | – | – | TACE | TACE+ Sorafenib | 5 |
Sun 2014 [34] | R | 66/15 | 68/13 | 53.9 ± 8.2 | 54.5 ± 7.9 | TACE | TACE+ Sorafenib | 5 |
Zhou 2014 [35] | R | 31/17 | 34/14 | 67.9 ± 10.8 | 71.9 ± 12.7 | TACE | TACE+ Sorafenib | 5 |
Wang 2015 [36] | R | 28 | 22 | – | – | TACE | TACE+ Sorafenib | 5 |
Lencioni 2016 [13] | R | 126/27 | 135/19 | 63.0 | 64.5 | TACE | TACE+ Sorafenib | 5 |
Kudo 2011 [26] | R | 168/61 | 174/55 | 70.0 | 69.0 | TACE | TACE+ Sorafenib | 5 |